Cargando…

Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study

BACKGROUND: Incidental findings (IFs) and secondary findings (SFs), being results that are unrelated to the diagnostic question, are the subject of an important debate in the practice of clinical genomic medicine. Arguments for reporting these results or not doing so typically relate to the principl...

Descripción completa

Detalles Bibliográficos
Autores principales: Saelaert, Marlies, Mertes, Heidi, Moerenhout, Tania, De Baere, Elfride, Devisch, Ignaas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990492/
https://www.ncbi.nlm.nih.gov/pubmed/32000764
http://dx.doi.org/10.1186/s12910-020-0452-0
_version_ 1783492511570853888
author Saelaert, Marlies
Mertes, Heidi
Moerenhout, Tania
De Baere, Elfride
Devisch, Ignaas
author_facet Saelaert, Marlies
Mertes, Heidi
Moerenhout, Tania
De Baere, Elfride
Devisch, Ignaas
author_sort Saelaert, Marlies
collection PubMed
description BACKGROUND: Incidental findings (IFs) and secondary findings (SFs), being results that are unrelated to the diagnostic question, are the subject of an important debate in the practice of clinical genomic medicine. Arguments for reporting these results or not doing so typically relate to the principles of autonomy, non-maleficence and beneficence. However, these principles frequently conflict and are insufficient by themselves to come to a conclusion. This study investigates empirically how ethical principles are considered when actually reporting IFs or SFs and how value conflicts are weighed. METHODS: A qualitative focus group study has been undertaken, including a multidisciplinary group of professionals from Belgian centres for medical genetics. The data were analysed thematically. RESULTS: All eight Belgian centres participated in this study. Ethical values were frequently referred to for disclosure policies on IFs and SFs. Participants invoked respect for patient autonomy to support the disclosure of IFs and opt-out options for IFs and SFs, non-maleficence for the professional delineation of reportable IFs and opt-out options for IFs and SFs and (the particular scope of) beneficence for the mandatory reporting of actionable IFs, the delineation of reportable IFs and a current decline of actively pursued SFs. Professional assumptions about patients’ genetic literacy were an important factor in the weighing of values. CONCLUSIONS: In line with the traditional bioethical discourse, the mandatory reporting of actionable IFs might be interpreted as a “technological, soft paternalism”. Restricting patients’ choices might be acceptable, but then its motives should be valid and its beneficent outcomes highly plausible. Hence, the presuppositions of technological, soft paternalism - patients’ inability to make informed decisions, normative rationality, the efficacy of beneficent outcomes and the delineated spectrum of beneficence - should be approached critically. Moreover, distributive justice should be considered an important value in the delineation of the current scope of the ethical debate on IFs and SFs. This study of guiding values may stimulate the debate on the ethical grounds for a solid policy on IFs and SFs internationally.
format Online
Article
Text
id pubmed-6990492
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69904922020-02-03 Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study Saelaert, Marlies Mertes, Heidi Moerenhout, Tania De Baere, Elfride Devisch, Ignaas BMC Med Ethics Research Article BACKGROUND: Incidental findings (IFs) and secondary findings (SFs), being results that are unrelated to the diagnostic question, are the subject of an important debate in the practice of clinical genomic medicine. Arguments for reporting these results or not doing so typically relate to the principles of autonomy, non-maleficence and beneficence. However, these principles frequently conflict and are insufficient by themselves to come to a conclusion. This study investigates empirically how ethical principles are considered when actually reporting IFs or SFs and how value conflicts are weighed. METHODS: A qualitative focus group study has been undertaken, including a multidisciplinary group of professionals from Belgian centres for medical genetics. The data were analysed thematically. RESULTS: All eight Belgian centres participated in this study. Ethical values were frequently referred to for disclosure policies on IFs and SFs. Participants invoked respect for patient autonomy to support the disclosure of IFs and opt-out options for IFs and SFs, non-maleficence for the professional delineation of reportable IFs and opt-out options for IFs and SFs and (the particular scope of) beneficence for the mandatory reporting of actionable IFs, the delineation of reportable IFs and a current decline of actively pursued SFs. Professional assumptions about patients’ genetic literacy were an important factor in the weighing of values. CONCLUSIONS: In line with the traditional bioethical discourse, the mandatory reporting of actionable IFs might be interpreted as a “technological, soft paternalism”. Restricting patients’ choices might be acceptable, but then its motives should be valid and its beneficent outcomes highly plausible. Hence, the presuppositions of technological, soft paternalism - patients’ inability to make informed decisions, normative rationality, the efficacy of beneficent outcomes and the delineated spectrum of beneficence - should be approached critically. Moreover, distributive justice should be considered an important value in the delineation of the current scope of the ethical debate on IFs and SFs. This study of guiding values may stimulate the debate on the ethical grounds for a solid policy on IFs and SFs internationally. BioMed Central 2020-01-30 /pmc/articles/PMC6990492/ /pubmed/32000764 http://dx.doi.org/10.1186/s12910-020-0452-0 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Saelaert, Marlies
Mertes, Heidi
Moerenhout, Tania
De Baere, Elfride
Devisch, Ignaas
Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
title Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
title_full Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
title_fullStr Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
title_full_unstemmed Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
title_short Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
title_sort ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990492/
https://www.ncbi.nlm.nih.gov/pubmed/32000764
http://dx.doi.org/10.1186/s12910-020-0452-0
work_keys_str_mv AT saelaertmarlies ethicalvaluessupportingthedisclosureofincidentalandsecondaryfindingsinclinicalgenomictestingaqualitativestudy
AT mertesheidi ethicalvaluessupportingthedisclosureofincidentalandsecondaryfindingsinclinicalgenomictestingaqualitativestudy
AT moerenhouttania ethicalvaluessupportingthedisclosureofincidentalandsecondaryfindingsinclinicalgenomictestingaqualitativestudy
AT debaereelfride ethicalvaluessupportingthedisclosureofincidentalandsecondaryfindingsinclinicalgenomictestingaqualitativestudy
AT devischignaas ethicalvaluessupportingthedisclosureofincidentalandsecondaryfindingsinclinicalgenomictestingaqualitativestudy